Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Titel:
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Auteur:
Zhu, Andrew X Finn, Richard S Edeline, Julien Cattan, Stephane Ogasawara, Sadahisa Palmer, Daniel Verslype, Chris Zagonel, Vittorina Fartoux, Laetitia Vogel, Arndt Sarker, Debashis Verset, Gontran Chan, Stephen L Knox, Jennifer Daniele, Bruno Webber, Andrea L Ebbinghaus, Scot W Ma, Junshui Siegel, Abby B Cheng, Ann-Lii Kudo, Masatoshi